SMI Response to Ibuprofen Use and Potassium Deficiency

SMI Response to Study on Ibuprofen Use and Potassium Deficiency

The New Zealand Self-Medication Industry (SMI) today urged caution in reacting to a new study suggesting a link between ibuprofen and potassium deficiency. In particular care should be taken to distinguish low-dose, short-term, over-the-counter (OTC) use from longer term use and misuse.

The study in The Medical Journal of Australia examines the effects of excessive ibuprofen ingestion in producing renal tubular acidosis (RTA), which can result in potassium deficiency.

The study in question was based on the experience of four patients who were taking up to 50 tablets of ibuprofen (14.4g) per day (12 times the recommended dose), who were found to have low blood potassium levels.

OTC ibuprofen is indicated at 1.2g/day for three days, and if combined with codeine, 1.2g/day for a maximum of three days.

SMI executive director Tim Roper said that anyone using ibuprofen at the doses recommended on the product labels should not be concerned by the study findings.

“As the study itself notes, RTA is a ‘complication of ibuprofen misuse’, and as such, will not impact those who follow the label instructions and use the product responsibly.

“As with any medicine, excessive use can be harmful. Ibuprofen has a long history of safe and effective use in New Zealand, when used according to the instructions.”

ENDS

© Scoop Media